Wentao Wu

Wentao Wu is mainly responsible for investment execution in HealthTech/MedTech sectors. Prior to joining Shunwei, he was engaged in HealthTech/MedTech investment at China Growth Capital. Prior to that, he was engaged in basic and clinical research in regenerative medicine and immunotherapy at Peking University Third Hospital.

Wentao has led the investment of several projects in the field of new drugs and medical devices, including Farbers Therapeutics, ReviR Therapeutics, Renerval Biotheraputics, Neurodom Medical, ZD Medical, Singleron Biotechnologies, InxMed, Health Biotech, 4B Biotechetc.

Wentao received his bachelor's degree from Wuhan University and master's degree from Peking University Health Science Center.